Gilead dou­bles down on HIV pre­ven­tion, treat­ment amid Covid set­backs and await­ing FDA de­ci­sion on long-act­ing can­di­date

Amid pre­dic­tions of HIV ad­vances un­rav­el­ing dur­ing Covid, Gilead Sci­ences is dou­bling down on pre­ven­tion, treat­ment op­tions and on-the-ground com­mu­ni­ty ef­forts, even as it awaits an FDA de­ci­sion on its long-act­ing can­di­date.

At the AIDS 2022 con­fer­ence be­gin­ning next week, Gilead will present new da­ta and stud­ies on HIV treat­ment Bik­tarvy and its long-act­ing PrEP and HIV can­di­date lenaca­pavir, but will al­so host a pan­el lay­ing out the de­tails — and im­por­tance — of com­mu­ni­ty col­lab­o­ra­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.